Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
November 15, 2024 06:00 ET
|
Sanofi - Aventis Groupe
Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland Lyon, le 15 novembre 2024 –...
Communiqué de presse - Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France
November 12, 2024 04:00 ET
|
Sanofi - Aventis Groupe
Aadil BEZZA rejoint Sanofi comme Directeur des Ressources Humaines France Paris, le 12 novembre 2024. Sanofi annonce la nomination d’Aadil BEZZA au poste de Directeur des Ressources Humaines France à...
Communiqué de presse - Sanofi obtient l’Autorisation de Mise sur le Marché d’Efluelda, son vaccin trivalent haute dose, pour la prochaine saison grippe 2025/2026
November 05, 2024 04:02 ET
|
Sanofi - Aventis Groupe
Sanofi obtient l’Autorisation de Mise sur le Marché d’Efluelda, son vaccin trivalent haute dose, pour la prochaine saison grippe 2025/2026 Paris, 5 novembre 2024. L’ANSM vient...
The Highly Anticipated FDA Approvals of Galderma’s Nemolizumab and Eli Lilly’s Lebrikizumab are Expected to Shift Dermatologists’ Perceptions of the Atopic Dermatitis Market
September 09, 2024 10:20 ET
|
Spherix Global Insights
EXTON, PA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Since its 2017 debut as the first advanced systemic treatment for atopic dermatitis (AD), Sanofi/Regeneron’s Dupixent has dominated the US market....
US Hematologists Express High Unmet Need in Treatments for Warm Autoimmune Hemolytic Anemia and Cold Agglutinin Disease
July 24, 2024 14:00 ET
|
Spherix Global Insights
EXTON, PA, July 24, 2024 (GLOBE NEWSWIRE) -- Autoimmune hemolytic anemia (AIHA) encompasses a group of rare disorders characterized by the destruction of red blood cells due to autoantibodies. Among...
Takeda’s Eohilia Sees Strong Early Adoption and Growth Potential in Eosinophilic Esophagitis, According to Spherix Global Insights
July 18, 2024 10:05 ET
|
Spherix Global Insights
EXTON, PA, July 18, 2024 (GLOBE NEWSWIRE) -- In February of this year, Takeda’s Eohilia (budesonide oral suspension) received FDA approval as the first and only oral therapy for eosinophilic...
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
July 12, 2024 07:00 ET
|
FluGen, Inc.
Combining FluGen's M2SR nasal spray flu vaccine with Sanofi's Fluzone High Dose shot generates superior results in older adults versus the shot alone.
Antidiuretic Drugs Market Size & Share to Exceed USD 1504.8 Million by 2034, at CAGR of 11.5%. "Fluid Harmony: Navigating the Antidiuretic Drugs Market for Optimal Hydration Solutions" – PMI Leads the Way
February 01, 2024 15:00 ET
|
PMI
Covina, Feb. 01, 2024 (GLOBE NEWSWIRE) -- “According to the recent research study, the Antidiuretic Drugs Market size was valued at about USD 558.7 Million in 2024 and expected to grow at CAGR of...
The International Myeloma Foundation is Creating an Award-Winning Tool for Nurses to Improve Myeloma Patient Outcomes in Underserved Communities
November 02, 2023 13:15 ET
|
International Myeloma Foundation
The International Myeloma Foundation wins the 2023 Sanofi HealthEquity Accelerator Award for their program which empowers nurses and tackles disparities.
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
September 14, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...